Jan-Paul Waldin Net Worth

Jan-Paul Waldin biography

Jan-Paul Waldin Esq. serves as Lead Independent Director of the Company. Mr. Waldin is a lawyer in Ontario, Canada and is a member of the Law Society of Upper Canada. He has been the principal of Waldin Barristers, a boutique civil litigation and advisory firm in Toronto, Canada, since January, 1981. Mr. Waldin practices trial and appellate advocacy principally in the area of complex corporate commercial litigation. He has acted as lead counsel in all levels of court in Ontario and Canada, including the Supreme Court of Canada, the Federal Court of Canada, the Ontario Court of Appeal, the Ontario Superior Court of Justice and before Canadian federal and provincial administrative tribunals. Mr. Waldin’s counsel and strategic advice is regularly sought by both publicly traded and closely held companies based in Canada, the European Union and the United States in connection with regulatory and administrative law matters, structuring shareholder relations and contentious corporate transactions. He has held directorships in private and multinational companies, principally in the manufacturing, aviation and pharmaceutical industries. A graduate of the University of Toronto and Osgoode Hall Law School, Mr. Waldin was called to the Ontario bar in 1976 and served his articles of clerkship under the late Mr. Justice Archie Campbell at the Policy Development Branch of the Ministry of the Attorney General for Ontario. He was Law Clerk to the Honourable Willard Z. Estey, then Chief Justice of the High Court of Justice of Ontario.

What is the salary of Jan Waldin?

As the Lead Independent Director of XBiotech Inc, the total compensation of Jan Waldin at XBiotech Inc is $137,000. There are 6 executives at XBiotech Inc getting paid more, with John Simard having the highest compensation of $10,810,400.

How old is Jan Waldin?

Jan Waldin is 71, he's been the Lead Independent Director of XBiotech Inc since 2018. There are 2 older and 7 younger executives at XBiotech Inc. The oldest executive at XBiotech Inc is Peter Libby, 73, who is the Independent Director.

What's Jan Waldin's mailing address?

Jan's mailing address filed with the SEC is 77 KING STREET WEST, SUITE 3000, TORONTO, A6, M5K 1G8.

Insiders trading at XBiotech Inc

Over the last 9 years, insiders at XBiotech Inc have traded over $50,443,920 worth of XBiotech Inc stock and bought 1,428,502 units worth $11,921,113 . The most active insiders traders include Street Financial S.A. Bay, Fondation Rennes y W Thorpe Mckenzie. On average, XBiotech Inc executives and independent directors trade stock every 48 days with the average trade being worth of $1,053,782. The most recent stock trade was executed by W Thorpe Mckenzie on 16 December 2021, trading 250,000 units of XBIT stock currently worth $2,500,000.

What does XBiotech Inc do?

xbiotech is developing a first-in-class monoclonal antibody (mabp1) to inhibit chronic inflammation. chronic (sterile) inflammatory responses are involved in the progression of many serious and common diseases. mabp1 is being investigated in many important areas of medicine, including: cancer, leukemia (phase 1); type 2 diabetes (phase2); psoriasis (phase 2); and vascular disease (phase 2). mabp1 is a true human™ antibody cloned from a natural human immune response and—unlike currently marketed antibodies—it has not undergone any modification to alter its function. it has exhibited the best potential tolerability and safety during the clinical trials. xbiotech has established a current good manufacturing practices (cgmp) program to commercialize its lead product candidate. the company has purchased land and designed a commercial-scale plant with 25,000l total bioreactor capacity. construction of the facility is planned to commence in 4th quarter 2011..

XBiotech Inc executives and stock owners

XBiotech Inc executives and other stock owners filed with the SEC include:

• John Simard,
  Chairman of the Board, President, Chief Executive Officer, Founder
• John Simard,
  Founder, Pres, CEO & Chairman
• Sushma Shivaswamy,
  Chief Scientific Officer
• Queena Han,
  Vice President - Finance and Human Resources, Secretary
• Dr. Sushma Shivaswamy,
  Chief Scientific Officer
• Queena Han CPA, B.A., CPA, C.G.A.,
  VP of Fin. & HR and Sec.
• W. Thorpe McKenzie,
  Independent Director
• Donald MacAdam,
  Independent Director
• Peter Libby,
  Independent Director
• Jan-Paul Waldin,
  Lead Independent Director
• Lisa Simard,
  Director of Corp. Strategy - XBiotech USA, Inc.
• Benjamín Guzmán,
  Sr. VP of Corp. Strategy & Fin.
• Daniel Vasella,
  Director
• Trey Benson,
  VP of Commercial Development
• Kelly Thornburg,
  SVP of Operations
• Fabrizio Bonanni,
  Director
• Dawn Mc Collough,
  VP Clinical Operations
• Michael Stecher,
  Medical Director
• Kalidip Choudhury,
  VP of Business Development
• James Scott Whitehurst,
  Chief Financial Officer
• Thomas Gut,
  10% owner
• Benjamin Guzman,
  Sr.VP Corp. Strategy & Finance
• Fondation Rennes,
  10% owner
• Street Financial S.A. Bay,
  10% owner